BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:59 PM
 | 
Oct 03, 2012
 |  BC Extra  |  Company News

FDA cancels pomalidomide, Exjade meeting

FDA cancelled a Nov. 8 meeting of the Oncologic Drugs Advisory Committee (ODAC) that was scheduled to discuss an NDA from Celgene Corp. (NASDAQ:CELG) for pomalidomide and an sNDA from Novartis AG (NYSE:NVS; SIX:NOVN) for Exjade

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >